Drusebjerg: The beginning of a bubble
According to Nordea senior strategist Henrik Drusebjerg we will soon see investors turning away from the high-priced pharmaceutical sector. He is especially worried about developments in the biotech sector over the past year or so.
by Stefan Singh Kailay
At a morning conference held by Medwatch last week, Nordea’s senior strategist Henrik Drusebjerg offered his take on the state of the global economy, before delving into the pharmaceutical and biotech sectors - and the senior strategist hardly offered a positive take on developments in these sectors.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
International biotech is in great shape
For abonnenter
Santaris: US IPO could be on the cards
For abonnenter
Novo company considers going public
For abonnenter
